Investor

Novartis Bioventure Fund

Last cheque observed Sep 2015. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietGrowth equity

Series BSeries ESeries A

Cheques on record
0%of best year0cheques in 12 months, 8 on record
Since the last cheque4066days00hrs00min00sec
Median round$32MRounds led0 of 8Exits2 from the portfolioMostly inUnited States, 100%
Pitch Novartis Bioventure Fund

Novartis Bioventure Fund highlights

  1. 01

    8 rounds on record

  2. 02

    Mostly Series B and Series E: 63% of its rounds

  3. 03

    2 exits from the portfolio

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first8 appearances

  1. 2015

    1 round

  2. Sept
    Proteostasis TherapeuticsSeries B · US$37MWith 7 others
  3. 2007

    1 round

  4. Jan
    Cylene PharmaceuticalsSeries C · US · rctech.com$44MWith 7 others
  5. 2005

    2 rounds

  6. Oct
    Nereus PharmaceuticalsSeries D · US$43MWith 11 others
  7. Mar
    Sirtris PharmaceuticalsSeries B · US · boston.bizjournals.com$27MWith 8 others
  8. 2004

    3 rounds

  9. Aug
    KalypsysSeries B$29MWith 7 others
  10. Jun
    PTC TherapeuticsSeries E · US$15MWith 9 others
  11. Jan
    PTC TherapeuticsSeries E · US$35MWith 8 others
  12. 2002

    1 round

  13. Mar
    PhenomixSeries A · US$12MWith 7 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed2 in all

PTC TherapeuticsListed$125MJun 2013
Sirtris PharmaceuticalsBought by GlaxoSmithKline$720MApr 2008

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Novartis Bioventure Fund. A count of rooms they were both in, not a relationship either has claimed.

HBM BioVenturesGrowth equity4rounds togetherBay City CapitalVC firm3rounds togetherAlta PartnersVC firm2rounds togetherCMEA VenturesVC firm2rounds togetherCredit Suisse First BostonInvestment firm2rounds togetherDelphi VenturesVC firm2rounds togetherHealthCapVC firm2rounds togetherNovo Holdings A/SGrowth equity2rounds togetherPOSCO BioVenturesVC firm2rounds togetherVulcan CapitalFamily office2rounds together

Quick answers about Novartis Bioventure Fund

What does Novartis Bioventure Fund invest in?

Novartis Bioventure Fund invests most often at Series B and Series E (63% of the rounds on record).

How active is Novartis Bioventure Fund?

8 investments on record, 0 of them in the last 12 months. The most recent was in Sept 2015.

How big are Novartis Bioventure Fund's cheques?

The median round it joins is $32M.

Does Novartis Bioventure Fund lead rounds?

Rarely, if at all: none of its 8 investments on record names it as the lead.

Where does Novartis Bioventure Fund invest?

Most of the companies it backs are in the United States (100%).

Is Novartis Bioventure Fund investing now?

No investments in the last 12 months; the latest was in Sept 2015.

Who does Novartis Bioventure Fund invest alongside?

Most often HBM BioVentures (4 rounds together), Bay City Capital (3 rounds together) and Alta Partners (2 rounds together).

What kind of investor is Novartis Bioventure Fund?

Novartis Bioventure Fund is a growth equity firm.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it